Valproate-Induced Bicytopenia: A Case Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Apr 4

PMID 35371645

Authors

Varun Jaitpal

Sushil Gawande

Affiliations

Soon will be listed here.

Abstract

This case report describes a 22-year-old male patient diagnosed with schizoaffective disorder. A multidrug regimen including olanzapine and lorazepam was initiated for the patient. Sodium valproate was added to the regimen in due course and it was associated with bicytopenia in the form of thrombocytopenia and leukopenia. Valproate was identified as the offending drug and further doses were withheld. Lithium was used as a substitute to valproate and the patient spontaneously recovered without any further complications. This case report highlights the necessity of periodic investigations and frequent logging of blood indices to counter the threat of fatal adverse drug reactions.

References

Bakchoul T, Marini I . Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):576-583. PMC: 6246020. DOI: 10.1182/asheducation-2018.1.576. View

Gajwani P, Tesar G . Olanzapine-induced neutropenia. Psychosomatics. 2000; 41(2):150-1. DOI: 10.1176/appi.psy.41.2.150. View

Kim D, Kim W, Lee C, Chun Y . Thrombocytopenia during intravenous valproic acid therapy in the neurological intensive care unit. J Clin Pharm Ther. 2020; 45(5):1014-1020. DOI: 10.1111/jcpt.13125. View

Rahman A, Mican L, Fischer C, Campbell A . Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009; 43(5):822-30. DOI: 10.1345/aph.1L617. View

Ing V . The etiology and management of leukopenia. Can Fam Physician. 2011; 30:1835-9. PMC: 2154209. View

Kumar R, Vidaurre J, Gedela S . Valproic Acid-Induced Coagulopathy. Pediatr Neurol. 2019; 98:25-30. DOI: 10.1016/j.pediatrneurol.2019.04.019. View

Singh A, Hungund B, Kumar L, Pattanshetti M . Clinico-haematological profile of patients with bicytopenia. Pathology. 2018; 50(5):540-548. DOI: 10.1016/j.pathol.2018.03.008. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Buoli M, Serati M, Botturi A, Altamura A . The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data. Drugs R D. 2017; 18(1):1-5. PMC: 5833908. DOI: 10.1007/s40268-017-0224-6. View

10.

Naseem S, Varma N, Das R, Ahluwalia J, Sachdeva M, Marwaha R . Pediatric patients with bicytopenia/pancytopenia: review of etiologies and clinico-hematological profile at a tertiary center. Indian J Pathol Microbiol. 2011; 54(1):75-80. DOI: 10.4103/0377-4929.77329. View

11.

Oh Y, Joung Y, Choi J . Incidence of Neutropenia with Valproate, Antipsychotics, and ADHD Medication Combination Treatment in Children and Adolescents. J Korean Med Sci. 2020; 35(28):e226. PMC: 7371460. DOI: 10.3346/jkms.2020.35.e226. View

12.

Vincenzi B, Greene C, Ulloa M, Parnarouskis L, Jackson J, Henderson D . Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. J Psychiatr Pract. 2016; 22(3):175-82. PMC: 5331927. DOI: 10.1097/PRA.0000000000000149. View

13.

Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J . A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatry Res. 2004; 129(2):159-69. DOI: 10.1016/j.psychres.2004.07.008. View